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ABSTRACT OF THE THESIS
ENZYME CATALYZED AND ULTRASOUND ASSISTED
TRANSFORMATION OF SELECTED POLLUTANTS
by
Yi Tan
Florida International University, 2017
Miami, Florida
Professor Xiaotang Wang, Co-major Professor
Professor Kevin O’Shea, Co-major Professor
The widespread use of synthetic drugs and as feed additives has resulted in the
release of large amounts of biologically active chemicals into the environment.
Exposure to environmentally relevant concentrations of chemicals can have
severe effects on human health. Therefore, effective degradation of these
synthetic, biologically active compounds is of paramount importance.
Diphenhydramine (DPH) has been selected as a target compound for ultrasound
remediation. The results demonstrated that ultrasound-induced degradation has
potential applications in managing aqueous media contaminated with DPH.
Atorvastatin and roxarsone have been selected as representative substrates for
chloroperoxidase (CPO) catalyzed transformation of pollutants. These studies
demonstrate atorvastatin and roxarsone can be degraded efficiently by CPO. The
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transformation products of each compound were identified and the mechanisms
of CPO catalysis postulated. This study provides a foundation for assessing the
feasibility of applying CPO in the remediation of water and soil contaminated with
pharmaceuticals and feed additives.
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CHAPTER I.
INTRODUCTION
1.1 The occurrence of pharmaceutical pollutants in water
Pharmaceuticals are manufactured compounds used to treat disease with highly
specific biological targets. The number of people on prescription drugs continues
to increase dramatically. The inappropriate disposal of unused and expired
medicines introduces pharmaceuticals into water systems. Most pharmaceuticals
are water soluble, and a large number are regularly detected in natural and
treated water systems, including drinking water supplies worldwide [1, 2]. In
addition, biologically active compounds have wide spread use for agricultural and
veterinary purposes and are often used as feed additives. These additives can be
resistant to metabolism and are persistent in the environment. A further
complication is the spread of contaminated manure when applied as fertilizer to
agriculture fields.

Figure 1.1 Sources, pathways, and sinks of pharmaceuticals [3].
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Selected pharmaceuticals have been detected both in effluent water samples and
aquatic animal bodies. The concentrations of 56 active pharmaceutical
compounds

were

reported

in

effluent

samples

across

the

USA [4].

Hydrochlorothiazide was found in every sample, while metoprolol, atenolol, and
carbamazepine were found in over 90% of the samples. Accumulation of
fluoxetine and gemfibrozil in fish liver tissue has been reported: Sertraline was
detected at concentrations as high as 19 and 545 ng/g in fillet and liver,
respectively [5].

Pharmaceuticals can have pronounced effects on aquatic and terrestrial
ecosystems. Laville and his coworkers tested the toxicity of human drugs on fish
to assess the potential effects of pharmaceuticals in water [6]. Nine
pharmaceuticals were tested on two fish hepatocyte models. The result showed
that eight of them were cytotoxic on both cell models with the observed specific
cell viability inhibition. Furthermore, a wide range of subtle impacts of
pharmaceuticals has been reported (Table 1.1), including effects on aquatic plants,
effects on fertility and reproduction in aquatic organisms and impacts on insect
physiology and behavior [7]. To evaluate the risk to humans, there is a
considerable lack of information, but the resistance to antibiotics and the
disruption of endocrine systems could be included.
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Table 1.1 Reported effects of pharmaceutical compounds on aquatic and terrestrial organisms [7].

Substrate

Medicine class

Reported effect

Erythromycin

Antibacterial

Inhibition of growth cyanobacteria and aquatic plants

Tetracycline

Antibacterial

Inhibition of growth cyanobacteria and aquatic
plants

Ibuprofen

Anti-inflammatory Stimulation of growth of cyanobacteria and
inhibition of growth of aquatic plants

Avermectins

Parasiticide

Adults insects: loss of water balance, disruption of
feeding and reduced fat accumulation, delayed
ovarian development, decreased fecundity and
impaired mating
Juvenile insects: delayed development, reduced
growth rates, development of physical
abnormalities, impairment of pupariation or
emergence and a loss of developmental symmetry

The amount of pharmaceuticals detected from wastewater treatment plant is
highly dependent on the type of treatment techniques being used [8]. In general,
conventional

water

treatment

strategies

do

not

effectively

remove

pharmaceuticals [9], thus development of new wastewater treatment methods is
highly desired.
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1.2 Treatment to remove pharmaceuticals in water
Pharmaceuticals can be removed by wastewater treatment process as shown in
Table 1.2. The removal rates expected for different wastewater treatment
processes are summarized in table 1.2. As a result of the different chemical and
physical characteristics of pharmaceuticals, advanced oxidation processes (AOP)
can achieve higher removal compared than conventional treatment processes.
Some of the AOPs can achieve 100% transformation of pharmaceuticals for
specific pollutants.
Table 1.2 Conventional and advanced wastewater treatment processes and their expected range
of removal efficiency for pharmaceuticals [10].

Removal range
(%)

Wastewater treatment
Conventional wastewater treatment

Activated sludge
Biological filtration
Primary settling
Coagulation, filtration and settling
Sand filtration

-193-100a

6-71
3-45
5-36
0-99

Advanced wastewater treatment

Ozonation
Ozonation/ultrasound and sonocatalysis
Ozonation and catalytic ozonation
UV irradiation
Photolysis (UV/hydrogen peroxide)
Dark and light Fenton
UV/TiO2
Biomembrane
Microfiltration and reverse osmosis
Reverse osmosis
Ultrasound
4

1-100
23-45
>9-100
29
52-100
80-100
>95
23-99
91-100
62-97
24-100

Advanced techniques to remove pharmaceuticals from wastewater include
oxidation with ozone [11], filtration by nanofiltration membranes [12] and
biodegradation with enzymes [13]. While these methods can be effective in the
degradation of select compounds, they have several limitations, such as overall
cost, low efficiency, toxic by-products and/or requirements for harsh conditions.

Advanced oxidation processes (AOPs) have been reported as a promising and
effective methods in eliminating pharmaceutical pollutants [14, 15]. During
advanced oxidation, hydroxyl radicals (OH·) are generated as the major reactive
oxygen species (ROS), and capable of destroying different organic compounds in
water [16, 17]. In aqueous solution, ultrasound of specific frequencies can lead to
ROS production as shown in Figure1.2. The ROS can destroy a wide variety of
organic compounds, and thus have great potential as an environmentally friendly
water treatment technique [18].

)))
H 2O 
H  OH 

O2 
 2O
H  O2 
 OOH 
O  H 2O 
 2 HO 
Figure 1.2 The generation of reactive oxygen species (ROS) by ultrasound
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1.3 Ultrasound wastewater treatment
Ultrasonic water treatment requires sound waves at frequencies greater than 20
kHz. Figure 1.3 shows the classification of sound determined by their different
range of frequencies.

Figure 1.3 Approximate frequency ranges corresponding to ultrasound,
with rough guide of some applications

Application of ultrasound to contaminated waste water leads to a series of events
which degrade organic pollutants. Several mechanisms have been proposed to
explain the ultrasonically induced decomposition process, primarily pyrolysis and
the production of ROS (OH·, H·and OOH·) mediated processes. The application
of ultrasound to an aqueous solution results in the formation of gas bubbles
caused by pressure gradients generated by ultrasound waves passing through
solution. These bubbles oscillate, in a process called cavitation, and ultimately
collapse at high temperature and pressure. According to Doulah’s model, the
energy released by imploding cavitation bubbles in the form of shock waves is an
important mechanism for the degradation of pollutants [19].
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Ultrasound has been used to degrade a number of pollutants, such as ethyl
paraben [20], ibuprofen [21], 5-methylbenzotrizole [22]. Ultrasonication is an
attractive water treatment technology because it requires no additives can be
effective on turbid solutions and is safe. Ultrasound can be potentially used in
remediation of pharmaceutical pollutants alone or as a pretreatment for
bioremediation process.

1.4 Peroxidase based enzymatic wastewater treatment
Biodegradation is another water treatment approach in which large molecules are
converted to small ones or oxidized to less biological active compounds by using
different types of microorganisms or enzymes. Microorganisms such as bacteria
and fungi [23, 24], and enzymes such as horseradish peroxidase (HRP) [25] have
been used in the transformation of organic pollutants in wastewater.

Peroxidases are a large family of redox-enzymes that catalyze the oxidation of a
substrate by hydrogen peroxide. They function primarily as detoxification
enzymes, oxidizing non-polar toxins such as pharmaceuticals to produce more
easily excreted polar compounds. Peroxidases degrade substrates via the
generation of free radicals, which eventually facilitate bond-cleavage reactions
[26]. Peroxidase was reported to be efficient in the treatment of phenolic
contaminants in wastewater treatment [27]. Peroxidases have attracted attention
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because of their ability to oxidize phenolic and nonphenolic compounds.

Typically, transformation of organic pollutants with peroxidase takes place in three
steps in the presence of hydrogen peroxide. The first step of the catalytic cycle is
the reaction between peroxidase and hydrogen peroxide, resulting in a Fe (IV)
cation radical of the enzyme (compound I). Compound I then reacts with the
substrate to form a Fe (IV) cation (compound II), which can further react with
another molecule of the substrate to reset the enzyme. During the reaction,
pollutant radicals are generated, which undergo degradation by participating in
reactions with other species (like O2) in solution or reactions with themselves or
other substrates in solution.

Figure 1.4 Peroxidase catalytic cycles [28]

In recent years, many studies have shown that enzyme treatment has several
advantages over conventional methods, since it is environmentally friendly, cost
effective and ease to handle. Furthermore, enzymatic transformation of organic
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pollutants can occur under relatively harsh conditions such as high salinity, low pH,
and extreme pollutant concentrations. More importantly, the high specificity of
enzymes enables the pollutants to be degraded efficiently in the presence of
natural organic matter present in many drinking water sources [29]. The most
commonly used peroxidases in pollutants degradation are chloroperoxidase
(CPO), horseradish peroxidase (HRP), lignin peroxidase (LiP), manganese
peroxidase (MnP), and lactoperoxidase (LPO). In this study, CPO will used to
catalyze the transformation of selected organic pollutants.

1.5 Properties of chloroperoxidase
Chloroperoxidase is one of the most versatile enzymes in heme-containing family
with one ferriprotoporphyrin IX prothetic group contained per enzyme molecule.
Chloroperoxidase, a heme-thiolate protein, was isolated and characterized by
Hager and his coworkers in 1966 [30] from the marine fungus Caldariomyces
fumago (C. fumago). Chloroperoxidase is heavily glycosylated (25-30%
carbonhydrates, two high-mannose N-glycosylation sites) with a molecular weight
of approximately 42,000 Daltons [31].

The capacity of CPO to perform diverse reactions makes it one of the most
versatile enzyme in heme-containing family. Chloroperoxidase catalyzes the
classical peroxidation reactions as well as P-450 like reactions, which include
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halogenation, hydroxylation, peroxidation and epoxidation [32]. When catalyzing
these reactions, CPO does not need cofactors but requires hydrogen peroxide
(H2O2)

or

tert-butyl

hydroperoxide

(t-BuOOH)

as

electron

acceptors.

Chloroperoxidase has been found in the ascomycete Emericella nidulans and the
basidiomycete Agaricus bisporus [33]. Chloroperoxidase is a highly hydrophilic
enzyme which makes it easy to dissolve in water. On the basis of all these
characteristics, CPO has been considered a promising candidate in wastewater
treatment applications.

1.6 Structure of chloroperoxidase
Despite functional similarities with other heme peroxidases, CPO has quite a
different

overall

folding

compared

to

most

classical

peroxidases.

Chloroperoxidase folds into a tertiary structure consists of eight helical segments
shown in different colors in figure 1.5 [34].

Figure 1.5 Crystal structure of CPO [34]
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The heme porphyrin ring is shown in red. Unlike other heme peroxidases that use
histidine as the proximal heme iron ligand, the proximal heme ligand in CPO
derives from the sulfur atom of a cysteine residue (like P450). Unlike P450 that
uses mainly non-polar groups as oxygen binding site in the distal pocket, the
substrate-binding site in CPO is formed primarily with polar amino acids [35, 36].
Hence, CPO is thought to have an active site hybridized from those of P450s and
peroxidases.

Figure 1.6 Stereoview of the CPO active site. Hydrogen bonds involving the distal side water
molecule, Glu183 (the proposed acid–base catalyst) and His105 are shown as dashed lines.
The histidine is only 3.5 å from the heme propionate that binds a cation [37].

In the distal pocket of CPO, the acid-base catalytic group is glutamic acid instead
of histidine find in most traditional heme peroxidases. Glutamic acid 183 can form
hydrogen bond with His 105 (only 3.5 Å away from the heme propionate) and
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function as a general acid-base catalyst. In Figure 1.6, the side chain of Glu 183
extends out from the distal helix to the position close to the peroxide binding site.
Furthermore, the hydrogen bound between His 105 and Glu 183 facilitates the
cleavage of heme bound O-O in the formation of compound I complex. Two
pheylalanine residues ( Phe 103 and Phe 186) stay close to the heme center that
serves as the gate keeper in controlling substrates access to the heme active site.

1.7 Substrate-binding pocket

Figure 1.7 Slice through a surface representation of CPO (including sugars attached to the
protein). The two channels leading to the active site are marked by arrows, and the heme is shown
in magenta. The halide binding site 2 (yellow sphere, bromide; blue, iodide) is located within the
narrow channel and the iodide specific binding site 3 at the end of the channel implicating a
pathway for halide access from the surface (site 1) to the heme though this narrow channel. [38]
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Unlike other peroxidases whose heme edge is available for substrate access, a
substrate binding pocket is required for CPO to hold the substrate in place. There
are two channels for substrate to enter the heme active center of CPO from the
enzyme surface, the narrow channel and the wide channel [38]. Most halide
binding sites are located in the narrow channel, which indicates it is the major
channel for halide ions to access the active oxoferryl center. The narrow channel
is mostly hydrophobic near the heme center but more polar and further away from
the center (Figure 1.7), which could hold the substrate in place for stereospecific
transformations.

1.8 Mechanism of CPO catalyzed reactions
The unique structure of CPO allows it to have multiple functions in catalyzing a
variety of reactions. Chloroperoxidase was found to follow the catalytic cycle of a
heme-thiolate haloperoxidase as shown in Figure 1.8. The catalytic cycle is
initiated by the heterolytic cleavage of the O-O bond in H2O2 by transferring two
electrons from the heme center. During the reaction, water and an oxo-ferryl
cation radical intermediate (compound I) are generated. Compound I is an active
intermediate and is involved in different types of chemical reactions. In one
pathway, compound I reacts with the substrate (RH) to form an oxoiron (IV) unit
(compound II). Then compound II can either be reduced back to the resting state
of the enzyme or undergo the classic peroxidase pathway.
13

Figure 1.8 Catalytic cycle of a heme-thiolate
(1) Resting ferric enzyme, (2) compound I, (3) compound X that releases hypohalous acid (HOX),
(4) protonated compound II, (5) compound II. Classic peroxidase reaction (e.g., phenol oxidation):
(2) ⇒ (4) ⇒ (5) ⇒ (1) (without oxygen transfer to the substrate); halogenation: (3) ⇒ (1);
hydroxylation (e.g. OH-transfer to benzylic carbon, see also Fig. 3: (4) ⇒ (1); oxygenation (e.g.
sulfoxidation): (5) ⇒ (1) (oxygen transfer to the substrate [39]

Compound I can also capture halide ion (X-) to give a hypochlorite adduct Fe-OX
(compound X). Compound X is unstable and can be protonated in acidic
environment. Eventually a hypohalous acid (HOX) forms and subsequently can
react with available organic substrates susceptible to electrophilic attack. Whether
the HOX is released to the solution or remains associated with COP remains
controversial [40, 41], but recent reports that describe the reaction between
chlorine and different substrates indicates that HOX diffuses into the solution
instead of binding to the active site [42].
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1.9 Reactions catalyzed by chloroperoxidase
Chloroperoxidase can catalyze a variety of reactions which include halogenation,
hydroxylation and many types of oxidation reactions. Halogenation by CPO
usually happens in solution at pH less than 3. Substrates susceptible to
halogenation include a variety of structures, such as polycyclic aromatic
hydrocarbons [43] and flavonoids [44].

Figure 1.9 Chlorinated products from the enzymatic halogenation of aromatic compounds by
chloroperoxidase in the presence of hydrogen peroxide and chloride ions. [43]

Figure 1.10 Enzymatic halogenation of flavones [44]
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Efficient hydroxylation of organic substrates has also been achieved with this
peroxidase. Chloroperoxidase is able to catalyze the hydroxylation of
1,2-dihydronaphthalene

with

t-butyl

hydroperoxide

as

oxidant

[45],

the

hydroxylation of the furan ring with hydrogen peroxide as an O2 donor [46]. All of
these are halide-dependent reactions and require the participation of halide ions.

Figure 1.11 Chloroperoxidase-catalyzed oxidation of 1,2-dihydronaphthalene [45].

Figure 1.12 Chloroperoxidase-catalyzed oxidation of the furan ring [46].

Besides halogenation and hydroxylation, CPO is able to catalyze a number of
oxidations independent of halide ions including oxidation of the amino group [47],
enantioselective sulfoxidation of thioanisole [33] and N-dealkylation [48], etc.
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Figure 1.13 Selected nonhalogenating oxidations catalyzed by CPO. 1 demethylation of
N,N-dimethylaniline; 2 oxidation of the amino group of chloroaniline into the corresponding nitroso
compound; 3 enantioselective sulfoxidation of thioanisole into the corresponding (R)-sulfoxide [33,
47, 48].

The goal of this study is to examine the potential effectiveness of ultrasound and
CPO-based enzymatic degradation for the removal of selected pollutants in water.
Detailed kinetic study and product analysis have been carried out to better
understand the transformation process. The kinetic study help for modeling
treatment for real applications. Based on the products identified, the mechanisms
of the transformation are postulated.
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CHAPTER II.
ULTRASOUND ASSISTED TRANSFORMATION OF DIPHENHYDRAMINE
2.1 Background
Diphenhydramine (DPH), also known as Benadryl, is a member of the
ethanolamine-based antihistamine family. It is one of the first antihistaminic
agents and was discovered in 1946. The main use of diphenhydramine is to treat
allergies. Diphenhydramine was the most commonly used antihistamine in 2007
[49]. Topical use of diphenhydramine to relieve itching is also common, including
as sprays and lotions. Diphenhydramine has been detected in water and in
shellfish bodies. The bioaccumulation factor for diphenhydramine is 118-218 in
marine shellfish [50], which has the potential to be transferred to humans through
marine food webs. Therefore, there is an urgent need to find an effective method
to remove DPH from natural water bodies and drinking water sources.

Figure 2.1 Chemical structure of Diphenhydramine (DPH)

The aim of this project is to investigate the potential application of ultrasound in
the degradation of DPH. Degradation efficiency and detailed kinetics studies were
conducted to assess the effectiveness of ultrasound for degradation of DPH in
aqueous media.
18

2.2 Materials and methods
2.2.1 Materials
The DPH standard was in the form of diphenhydramine hydrochloride (10 g) and
was purchased from MP Biomedicals, LLC. The HPLC grade acetonitrile was
purchased from Fisher Scientific. All reagents were used as received. All aqueous
solutions were prepared with Millipore filtered water and volumetric lab
equipment.
2.2.2 Sample preparation
An ultrasonic generator equipped with a 500 ml reaction vessel was used to
conduct the study. All solutions were prepared in a 500 ml volumetric flask using
Millipore filtered water. The mixture was then transferred to the ultrasonic vessel.
The frequency, pulse, amplitude and repetition of the generator were all set in the
medium value. The solution was gently purged with O2 for 15 min and rubber
septum was used to seal the vessel. The reaction vessel was placed in a tank
filled with ice water to maintain a temperature around 10 °C. A 10 ml syringe was
filled with oxygen and inserted into the vessel to replace the solution being
collected for sampling. The syringe was rinsed with deionized water between
sample collections. Samples were collected at different treatment times for HPLC
analysis.
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2.2.3 HPLC Analysis
The concentration of DPH was monitored by a Varian ProStar HPLC, equipped
with a ProStar 410 autosampler and a ProStar 335 photodiode array detector
under the following conditions: a reversed phase C18 column (5µl, 250 × 4.6 mm)
with a constant solvent ratio of A: B 60:40. Solvent A was 20 mM NaH2PO4
acidified to pH 2.84 using H3PO4. (pH might be lower to avoid trailing to get a
better peak shape.) Solvent B was acetonitrile. A volume of 30μl sample was
injected and a flow rate of 1ml/min was used for elution. The detection wavelength
was set at 216 nm.
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2.3 Results and discussion
2.3.1 Transformation of DPH as a function of concentration

Figure 2.2 Effect of concentration on ultrasound degradation of DPH
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The ultrasonically induced degradation was monitored at different initial
concentrations varying from 4.6 to 72.5 μM (Figure 2.2). The concentration was
plotted as a function of treatment time and the data fit to the best line with the
slope representing the observed degradation rate. The results demonstrate
ultrasound was effective for the degradation of DPH over different concentrations.
To minimize the effect of by-products only the first 10-20% degradation was
considered in measuring the initial degradation rate. The observed initial rates are
0.386 μM • min-1 for 4.6 μM, 0.587 μM • min-1 for 6.2 μM, 0.815 μM • min-1 for 18.5
μM, 0.999 μM • min-1 for 40.1 μM, 1.171 μM • min-1 for 56.0 μM, 1.461 μM • min-1
for 72.5 μM (Table 2.1). Based on these results, the initial rate incresed as the
concentration increased,

which can be explanied by the existence of more DPH

molecules at high concentration to be degradated by the steady state of ROS
generated or decomposed by pyrolysis.
Table 2.1 Initial rate under different concentrations

C (μM)

R (μM • min-1)

4.6

0.386

6.2

0.587

18.5

0.815

40.1

0.999

56.0

1.171

72.5

1.461
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The degradation of different concentrations of DPH as a function of time is
illustrated in Figure 2.3. The plot of DPH removal, [DPH] / [DPH]0 as a function of
time shows less time in the removal of DPH at low concentration (4.6 μM and 6.2
μM). As concentration increases (56 μM and 72.5 μM), the removal efficiency
decreased.

[DPH] (μM)

Figure 2.3 Removal of DPH during ultrasound treatment

Ultrasound leads to production of steady state concentration of ROS which will
have a pronounced effect on overall degradation of the target compound.
Therefore, when there is an excess number of DPH molecules, it is logical
treatment times need to increase to generate more ROS to achieve complete
degradation.
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2.3.2 Kinetic studies
Evaluation of reaction kinetics can provide useful mechanistic information and
important parameters for the assessment and modeling of ultrasound treatment.
First order reaction and Langmuir-Hinshelwood kinetic model were applied to
provide insight about the degradation process.
Pseudo-first-order
In previous studies, it was shown that ultrasonic assisted degradation follows the
first order kinetics as shown below:
In(

Ct
) = −kt
C0

Where Ct is the concentration (at time t) and C0 is the initial concentration (at time
0), and k is the first-order rate constant (min-1). The first order rate constant k can
be extracted from the slope of plot ln (Ct/C0) as a function of reaction time.

[DPH] (μM)

Figure 2.4 First-order plot under different DPH concentrations
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The observed first-order rate constants are 0.133 min-1 for 4.6 μM, 0.147 min-1 for
6.2 μM, 0.061 min-1 for 18.5 μM, 0.029 min-1 for 40.1 μM, 0.025 min-1 for 56.0 μM,
0.025 min-1 for 72.5 μM (Table 2.2). The rate constant becomes constant as the
concentration of DPH > 40μM), which indicates that the reaction system becomes
saturated.
Table 2.2 Pseudo-first-order rate constants under different concentrations

[DPH] (μM)

k

4.6

0.133

6.2

0.147

18.5

0.061

40.1

0.029

56.0

0.025

72.5

0.025

Langmuir- Hinshelwood
Further analysis of the degradation process was achieved by employing kinetic
models for interfacial process. Since the degradation process is heterogeneous,
and can occur at the gas-liquid interface (at surface of cavitation bubble), the
Langmuir-Hinshelwood kinetic model can be applied to provide insight about the
degradation on localized substrate due to pyrolysis and degradation reactions
from reactive oxygen species at the interface.
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The form of the Langmuir-Hinshelwood model is given as:
1
1
1


r0 k r KC 0 k r

Where r0 is initial rate, C0 is the initial concentration of substrate. The value kr is
the reactivity coefficient, and K is the equilibrium constant.
3

2.5

1/r0(min/μM)

2

C0

1/C0

r0

1/r0

4.6
6.2
18.5
40.1
56.0
72.5

0.217
0.161
0.054
0.025
0.018
0.014

0.386
0.587
0.815
0.999
1.171
1.461

2.591
1.704
1.227
1.001
0.854
0.684

1.5

y = 7.9492x + 0.6956
R² = 0.9439

1

0.5

0
0

0.05

0.1

0.15

0.2

0.25

1/C0 (μM-1)

Figure 2.5 Langmuir- Hinshelwood plot of ultrasound treatment of DPH. The insert table is the
initial rate at different concentrations of DPH and the inverse of them.

The Langmuir-Hinshelwood kinetic parameters K and kr were determined by the
slope and intercept of plot 1/r0 as a function of 1/C0 (Figure 2.5), which yields K =
0.02 L/μM and Kr = 1.4 μM/min·L under our experimental conditions. The kinetic
parameters obtained provide insight about both surface adsorption and oxidative
reactivity.
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2.4 Conclusion
During ultrasonic cavitation, three zones are generated: hot spot, gas-liquid
interface and bulk solution. The hot spot possesses extremely high pressure (100
atm) and temperature (5000K), which will decompose H2O and O2 to produce
reactive oxygen species (ROS). Reactive oxygen species play distinguishable
roles in the degradation process. Once generated, ROS can diffuse to the
interface and bulk solution which contains organic pollutants, subsequently
leading to oxidative degradation of DPH.

Our study demonstrated that DPH was effectively degraded under ultrasound
treatment, and the concentration of DPH was critical and correlated to the initial
rate constant during treatment. The process was most effective under relatively
low concentrations, at which DPH could be degraded by 50% in the first 5 min.
The degradation process followed pseudo-first-order kinetics. The first-order rate
constants were determined in the presence of different concentrations of DPH.
The rate constants decrease as the concentrations of DPH increase and level off
as the DPH reaches > 40μM, which indicates that the reaction system is subject
to saturation kinetics at higher concentrations. Finally, the Langmuir-Hinshelwood
kinetic model was successfully applied and the parameters obtained (K=0.02
L/μM and Kr=1.4 μM/min·L) can provide insight about the degradation process at
the gas-liquid surface.
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Our study leads to a better fundamental understanding of ultrasound induced
degradation of DPH, which demonstrated that ultrasound-induced degradation
has great potential to serve as an effective method for treatment of aqueous
media contaminated with DPH. Furthermore, the first order kinetic study provided
in depth knowledge about the ultrasound assisted degradation, which can also
help to predict the required reaction time to reach the treatment objective. The
Langmuir-Hinshelwood kinetic model provide insight about the localization of DPH
at the interface as well as the subsequent reactivity, which are critical in assessing
practical water treatment technologies.
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CHAPTER III.
CPO CATALYZED TRANSFORMATION OF ATORVASTATIN
3.1 Background
Atorvastatin (ATV), also known as Lipitor (Figure 3.1), is one of the most
commonly prescribed drugs in the US and Europe [51]. It inhibits the activity of
hydroxymethylglutaryl-CoA (HMG-COA) involved in cholesterol biosynthesis, thus
blocks the production of cholesterol. Atorvastatin has a molecular formula of
C66H68CaF2N4O10 with a molecular weight of 1155.34 g/mol. It is a white
crystalline powder with a dissociation constant (pKa) of 4.46.

Figure 3.1 Chemical structure of ATV

The

discovery

of

statins

was

a

breakthrough

in

the

prevention

of

hypercholesterolemia and related diseases. From 2002 to 2009, atorvastatin
became the world’s best-selling drug, with more than 9.3 billion dollars in sales
during that time. The presence of ATV in sewage efﬂuents and surface waters has
been observed at concentrations of mg/L levels [52]. Moreover, it has been
detected in many water samples including treated sewage samples. When
present to aquatic environments, ATV could be harmful to the aquatic ecosystem,
adversely affecting aquatic organisms.
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The aim of this project was to investigate the potential application of CPO in the
degradation of ATV. The rate of CPO in the degradation of ATV was measured.
The CPO transformation of ATV was run at a range of Cl- and Br- concentrations,
at buffered pH, and over a range of concentrations of H2O2. The enzyme kinetics
and degradation pathway were studied under the optimized conditions.

3.2 Materials and methods
3.2.1 Materials
Chloroperoxidase (CPO) was isolated and purified from Caldariomyces fumago
according to the protocol reported by Morris and Hager [31]. Chloroperoxidase
with Reinheitszahl value (Rz, purity index of heme enzymes) of 1.3 or higher was
used for all experiments. The concentration of CPO was determined by
measuring the absorbance at 398 nm using a molar extinction coefficient of
91,200 M−1cm−1 [31].

Atorvastatin was purchased from AK Scientific (Union City, CA, USA). All solvents
used were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA) and
were of HPLC grade or Optima® LC/MS grade. Millipore Milli-Q water (18.2 MΩ)
was used throughout.
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3.2.2 Sample preparation
The reaction was conducted in a buffer solution with 100 mM KH2PO4 and 20 mM
KBr at pH 3.5. Atorvastatin was dissolved in methanol as the stock solution. H2O2
stock was prepared by diluting 35% concentrated H2O2 solution with buffer. Drug
stock was added into the buffer solution to get a sufficient mix. The CPO stock
solution was then added as a catalyst of the reaction. The H2O2 stock solution was
subsequently added to initiate the reaction. Upon completion of the reaction, ethyl
acetate was used to extract the filtrate and quench the reaction. The metabolites
were extracted into the top organic layer during the liquid-liquid extraction while
the CPO and salt in buffer remained in the aqueous layer. The top organic layer
was separated and nitrogen gas was used to evaporate the organic solvent. The
residues containing metabolites were then dissolved in different solvents for
instrumental analysis. All samples were stored at 4 °C before measurements.
3.2.3 UV-Visible spectrophotometry
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to record the
optical data. The full scan mode was used to monitor the real-time absorbance
change as a function of time. Using the spectra obtained under the full scan
mode, the transformation from the reactant to products was observed. The kinetic
parameters of the reaction were extracted by monitoring the absorbance change
at a selected wavelength (241 nm for ATV) as a function of time.

31

3.2.4 UPLC-MS spectrophotometry
Agilent 1290 Infinity UPLC system coupled with an orthogonal geometry
Electrospray Ionization (ESI) equipped Agilent 6530 Q-TOF mass spectrometer
was used for the separation and identification of the metabolites. An Agilent
ZORBAX Eclipse plus C18 Rapid Resolution High Definition (RRHD) column (3.0
×100 mm, 1.8 µm) was applied, the column temperature was set at 30 °C. An
infinity 1290 automatic injector was used to inject 1 µL of the sample to the
column. A flow rate of 0.4 mL/min was used and an aqueous mobile phase A
consisting 5 mM ammonium formate with 0.1% formic acid and the organic mobile
phase B consisting of 90% acetonitrile and 10% water with 0.1% formic acid. The
optimized chromatographic gradient was at 0 minute, 50% A and 50% B and B
increased linearly to 95% over 6 minutes, this gradient was maintained for 4
minutes. Scanning was performed from m/z 100 to 1000 in the positive ion mode.
The accurate mass of the molecular ions was processed using the Agilent
MassHunter Qualitative Analysis software.
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3.3 Results and discussion
3.3.1 Transformation of ATV by CPO
The transformation of ATV catalyzed by CPO is monitored by UV-vis optical
spectrophotometry. Atorvastatin showed a strong absorption at 241 nm as shown
in Figure 3.2. The spectra of ATV with only H2O2 or CPO shows similar spectral
features to ATV, indicating that no reaction occurs. However, the spectra of
solution of ATV after addition of H2O2 or CPO shows a distinct decrease in 241 nm
and a concomitant increase in 341 nm. The change of the spectral clearly showed
the transformation of ATV. Control groups of only CPO and H2O2 were also
conducted to exclude the absorbance change caused by the addition of H2O2 and
CPO.

Figure 3.2 Transformation of ATV by CPO. ATV=8.66 µM, CPO=4.8 nM, H2O2= 0.5mM
Phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH 3.5
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The CPO-induced transformations of ATV at different time points are shown in
Figure 3.3. The spectra was collected at 0, 40, 80, 120, 160 and 200 sec after the
reaction, including 25 sec to collect data for full spectrum. The ATV spectra as a
function of treatment time show an incremental decrease at 240 nm, with the
growth of a band at 341 nm. Interestingly, an isosbestic point was observed
around 300 nm. This point indicated that at λ=300 nm, the UV absorbance of ATV
and the generated products remained constant throughout the whole reaction.
The conversion from the reactant to the product(s) is clearly indicated in the graph,
providing fundamental information for further kinetic studies and product
identification. The reaction rate decreases gradually reflected by the relative
change in absorbance with time.

Figure 3.3 Transformation of ATV by CPO at different times. ATV=8.66 µM, CPO=4.8 nM,
H2O2= 0.5mM Phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH 3.5
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3.3.2 The effect of pH
The effect of pH was investigated to determine the optimal pH for CPO catalyzed
ATV transformation (Figure 3.4).

Figure 3.4 The effect of pH on ATV transformation
ATV=8.66 µM, CPO=4.8 nM, H2O2= 0.5mM Phosphate buffer: 100 mM K2HPO4, 20 mM KBr,
pH 2.5, 3, 3.5, 4, 4.5 and 5 respectively. Monitored by UV at λ=241nm

The experiment was conducted in the pH range of 2.5-5.0. In the presence of 20
mM Br-, the optimum pH for the transformation of ATV is 3.5. The transformation
rate of ATV increased significantly with increasing pH, and reached a maximum
around pH 3.5. The degradation efficiency decreased sharply at pH > 3.5. This
change indicated the transformation of ATV was a pH-dependent process, which
could be attributed to the change in the protonation state of the ionizable group in
compound X of CPO. Compound X was reported to be involved in most CPO
catalyzed halide dependent reactions [53], and releases the powerful oxidizing
agent (HXO) under acidic conditions.
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3.3.3 The effect of hydrogen peroxide concentration
To determine the optium concentration of hydrogen peroxide, the experiment was
carried out in the presence of varying concentrations of H2O2 (Figure 3.5).

Figure 3.5 The effect of H2O2 concentration on ATV transformation
ATV=8.66 µM, CPO=4.8 nM, phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH=3.5,
H2O2= 0, 0.35, 1.06, 2.11, 3.17, 4.22 and 5.28 mM respectively. Monitored by UV at λ=241nm

Control reaction showed the addition of H2O2 is required, and rate of
transformation increased as the concentration of H2O2 increased up to 2 mM. The
H2O2 concentrations above 2 mm decreased the transformation rate. One
possible explanation is that excess H2O2 deactivates or degrades the enzyme.
High concentrations of H2O2 have been reported to destroy the porphyrin
prosthetic group in most heme containing enzymes [54]. Excess H2O2 may also
inhibit the enzymatic process because of competition with halide ions required for
the formation of compound X. A low concentration of H2O2 was applied for CPO
induced transformation of ATV.
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3.3.4 The effect of halide ions
Since many of the reactions catalyzed by CPO are either dependent upon or
accelerated by halide ions [55], it is vital to understand the effect of chloride (Cl-)
and bromide (Br-) ions. Figure 3.6 shows the relationship between the rate of ATV
degradation and the ratio of Cl- or Br- to ATV.

Figure 3.6 The effect of halide ions on ATV transformation
ATV=15 µM, KBr=1.5, 4.5, 7.5, 12 and 15 µM respectively, KCl=0.15, 0.3, 0.75, 1.05, 1.35 and 1.5
mM respectively, CPO=2.4 nM, H2O2=15.5 µM Monitored by UV at 241nm

There was no transformation observed without Cl- and Br-. Moreover, the
transformation rate was proportional to the ion to drug ratio in a certain range
(From 0.1-1 for Br- and 0.7-6.7 for Cl-). The transformation rate in the presence of
Br- was more efficient when compared to Cl-. This could be attribute to the efficient
distinction in the production of HBrO and HClO or their ability to oxidize ATV within
CPO environment.

37

3.3.5 Product identification
I used HPLC-MS to identify the products from CPO-catalyzed ATV transformation.
The results are shown below.

Retention time (min)

Mass to charge ratio (m/z)

Retention time (min)

Figure 3.7 The chromatogram and MS spectra of ATV
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Mass to charge ratio (m/z)

Mass to charge ratio (m/z)

Mass to charge ratio (m/z)

Figure 3.8 The chromatogram and MS spectra of metabolites
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From the chromatogram obtained, we can see there are three major peaks
showing different retention times, suggesting the formation of putative products.
When extracting the mass spectra from the middle peak (5.5 min), it shows a
co-elution of two different substances, ATV at m/z 559 and one of the metabolites
at m/z 557. The peak at 4.9 min was giving an ion at m/z 575, which indicates the
hydroxylation of aromatic rings to the parent compound. The peak eluted at 5.9
min shows a molecular ion [M+H]+ at m/z 557, which has the same m/z ratio as
the peak eluted at 5.5 min. This result indicated that there were two lactone
isomers formed based on the OH substituted structure. Based on these
observations, four metabolites from CPO catalyzed ATV transformation are
proposed as listed in Table 3.1.
Table 3.1 Accurate-Mass LC-Q-TOF-MS data for the identification of ATV and its metabolites.
Name

Formula

Rentention time

Experimental

Theoretical

(min)

mass (m/z)

mass (m/z)

ATV

C33H35FN2O5

5.589

559.2661

558.2530

o-OH-ATV

C33H35FN2O6

4.937

575.2551

574.2479

p-OH-ATV

C33H35FN2O6

4.937

575.2551

574.2479

o-OH-ATV-lactone

C33H33FN2O5

5.553

557.2391

556.2374

p-OH-ATV-lactone

C33H33FN2O5

5.935

557.2464

556.2374

The theoretical mass to charge ratios were calculated for ATV and its metabolites
as a reference to their experimental values. These products were confirmed by
different retention times and accurate mass-to-charge ratios. For hydroxylated
metabolites, the isomer’s peak were detected at the same retention time, while for
hydroxylated lactone metabolites the retention times were different.
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3.3.6 Mechanism of CPO-catalyzed ATV transformation
On the basis of LC-MS and UV-Vis spectroscopic studies, the mechanism of
CPO-catalyzed transformation of ATV is proposed (Figure 3.9).

Figure 3.9 Proposed mechanism of ATV transformation (C=Cl- or Br-)
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3.4 Conclusion
In summary, we found that CPO readily transformed ATV over a range of acidic
solutions (2.5 to 5) with the fastest transformation observed at pH=3.5. A range of
[H2O2] was tested and the maximum rate was achieved when H2O2 concentration
reached 2.11 mM. However, further addition of H2O2 repressed the transformation
possibility because of deactivation of the enzyme caused by high concentration of
H2O2. The important role halide ion played in CPO catalyzed transformation of
ATV was demonstrated; although, no halogenated products are identified.
Bromide ion was shown to be more potent in CPO catalyzed transformation of
ATV than chloride ion, which could be attributed to the different binding affinity of
Cl- or Br- to CPO.

The LC-MS analysis proved to be an efficient technique for determining the
metabolites of ATV. My result is in good agreement with the reported mechanism
of ATV transformation [56]. Atorvastatin and its major hydroxylated metabolites,
2-ATV and 4-ATV, are present in equilibrium with their corresponding inactive
lactone forms. The mechanism proposed includes the formation of an oxoferryl
π-cation radical intermediate (compound I), and a hypohalite adduct (compound
X). The pH dependent experiment suggests the protonation of compound X under
acidic conditions, which can release HOX from the active site and subsequently
reacts with ATV to initiate an electrophilic attack.
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The study provided a fundamental understanding of enzymatic based
transformation of ATV. The effect of halide ion and pH helps our understanding of
how environmental factors would affect the degradation in real application.
Identification of products shed light into understanding of the characteristic of
CPO-catalyzed reactions. Based on the proposed degradation pathway, the
associated toxicity of intermediates/products can be studied to assess their
impact on environment. These studies provided in depth knowledge about the
enzymatic degradation, which are critical for environmental friendly water
treatment technologies.
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CHAPTER IV.
CPO CATALYZED TRANSFORMATION OF ROXARSONE
4.1 Background
Roxarsone (ROX), 4-hydorxy-3-nitrobenzenearsenic acid (Figure 4.1), is used as
a common feed additive in poultry industry. It is a derivative of phenylarsonic acid
as it has an arsenic directly linked to a benzene ring. Roxarsone is used to
improve feed efficiency and increase weight gain in chicken and pigs. Figure 4.2
shows how ROX is introduced into the environment. Roxarsone is a threat to
humans since arsenic species has been recognized as a toxic metalloid
presented in rivers [57] with a high solubility in water.

Figure 4.1 Chemical structure of Roxarsone (ROX)

Figure 4.2 Fate of ROX used as feed additives [58]
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Studies have shown that arsenic is readily released to surface and ground water
from poultry litter [58], leading to a serious ROX pollution problem. With the
development of nanotechnology, the adsorption of ROX in aqueous solution was
investigated [59], however, this technique has limitations for drinking water. AOPs
have been used in the treatment of organoarsenicals like ROX [60, 61]. Hydroxyl
radical mediated processes lead to the degradation of ROX however the
non-selective nature of OH·is a problem for practical applications. Furthermore,
advanced oxidation treatment drives transformation of organoarsenicals to
inorganic forms As (V) which requires removal to prevent arsenic presence in
discharged agricultural wastewater.

The goal of this study was to examine the potential effectiveness of CPO-based
enzymatic transformation for the removal of ROX. The solution pH, the
concentration of halide ion and the concentration of H2O2 were varied to identify
optimal conditions. Detailed kinetic and product studies were carried out under
optimal conditions. The major-products were identified, and the mechanism of
ROX transformation was proposed.
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4.2 Materials and methods
4.2.1 Materials
Chloroperoxidase (CPO) was isolated and purified from Caldariomyces fumago
according to the protocol reported by Morris and Hager [31]. CPO with Rz of 1.3
or higher was used for all experiments. The concentration of CPO was
determined by measuring the absorbance at 398 nm using a molar extinction
coefficient of 91,200 M−1cm−1 [56].

Roxarsone was purchased from Tokyo Kasei Kogyo Co., Ltd, (Tokyo, Japan). All
other chemicals and solvents were purchased from Thermo Fisher Scientific
(Waltham, MA, USA) and are of either reagent or analytical grade. All aqueous
solutions were prepared with Millipore filtered water (18.2 MΩ) and volumetric lab
equipment.
4.2.2 Sample preparation
The reaction was conducted in 100 mM KH2PO4 buffer containing 20 mM KBr at
pH 3.5. Roxarsone was dissolved in buffer as the stock solution. H2O2 stock was
prepared by diluting 35% concentrated H2O2 solution into the buffer solution.
Roxarsone stock was added into the buffer solution and mixed thoroughly. The
CPO stock solution was then added as a catalyst of the reaction. The H2O2 stock
solution was subsequently added to initiate the reaction. Upon completion of the
reaction, ethyl acetate was used to extract the products and quench the reaction.
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During extraction, the metabolites were extracted into the top organic layer during
the liquid-liquid extraction while CPO and salt remained in the bottom aqueous
layer. The top organic layer was separated and nitrogen gas was used to
evaporate the solvent. The residues containing metabolites were dissolved in
different solvents for instrumental analysis. Samples were stored at 4 °C before
use.
4.2.3 UV-Visible spectrophotometry
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to monitor the
progress of the reaction. The full scan mode was used to monitor the real-time
absorbance change as a function of time. Based on the spectra obtained under
the full scan mode, the conversion of the reactant to products was observed. To
determine the rate of ROX degradation, the kinetic mode was used to monitor the
absorbance change at a selected wavelength (223 nm for ROX) as a function of
time. The rate was calculated according to the equation below:

Rate(µM⁄𝑚𝑖𝑛) =

𝐴0 − 𝐴𝑡
0.1087 × (𝑡0 − 𝑡𝑡 )

A0 is the absorbance monitored at time t0, At is the absorbance monitored at time
tt, and 0.1087 (µM-1 cm-1) is the measured extinction coefficient of ROX at 223
nm.
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4.2.4 NMR characterization
Nuclear magnetic resonance (NMR) spectroscopy were employed to identify the
major transformation products. The NMR experiments were carried out on a
Bruker 400 MHz NMR spectrometer operating at a proton frequency of 400.13
MHz. The samples were all dissolved in deuterated solvents before transferring to
5 mm NMR tubes. All spectra were recorded at 298 K using standard pulse
programs from the manufacturer.
4.2.5 Mass Spectrometry
A volume of 100 L of the sample was mixed with 10 L of Agilent ESI tuning
solution (p/n G2421-60001; L/N A117489) and 890 L of acetonitrile, for a final
concentration of 1 mg/L. A blank was prepared similarly, using 100 L of acetone
(OptimaTM grade) instead of the sample. Using a syringe pump (3 μL/min), the
obtained solution was infused into the Turbo VTM ESI source of an AB SCIEX
QTRAP 5500® triple quadrupole mass spectrometer operating in full scan
(100-650 Da) in negative mode. Product ion scan (Target→50-300 Da) was
performed at medium collision gas pressure and at 40 eV of collision energy.
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4.3 Results and discussion
4.3.1 Transformation of ROX by CPO
The transformation of ATV catalyzed by CPO is shown in Figure 4.3. Roxarsone
showed a strong absorption at 223 nm. With the addition of only H2O2 or CPO, the
spectral pattern remains essentially unchanged, indicating no reaction occurs.
When H2O2 and CPO were mixed together with ROX, a distinct spectrum was
observed, with a decrease in 223 nm and a concomitant increase in 400 nm. The
change of the spectral pattern clearly showed the transformation of ROX to
products. Control groups of only CPO and H2O2 were also conducted to exclude
the absorbance change due to addition of H2O2 and CPO.

Figure 4.3 Transformation of ROX by CPO.ROX=25 µM, CPO=4.8 nM, H2O2= 0.31mM
Phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH 3.5
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4.3.2 The effect of pH
The effect of pH was investigated to determine the optimal pH for CPO catalyzed
ROX transformation (Figure 4.4).

Figure 4.4 The effect of pH on ROX transformation
ROX=25 µM, CPO=4.8 nM, H2O2= 0.69 mM Phosphate buffer: 100 mM K2HPO4, 20 mM KBr,
pH 2.5, 3, 3.5, 4, 4.5 and 5 respectively. Monitored by UV at λ=223nm

The experiment was conducted in the pH range of 2.5-5.0. In the presence of 20
mM Br-, the optimum pH for the transformation of ROX is 3.5. The transformation
rate gradually increased when pH increased from 2.5 to 3.5 and decresed from
3.5 to 5.0. This trend indicated that the transformation of ROX was a
pH-dependent process, which could be attribute to the change in the protonation
state of the ionizable group in conpound X. Compound X was reported to be
involved in most CPO catalyzed halide dependent reactions [53], and was able to
release the powerful oxidizing agent (HXO) under acidic conditions.
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4.3.3 The effect of hydrogen peroxide concentration
To examine the effect of H2O2 concentration on the transformation of ROX, the
experiment was carried out in the presence of varying concentrations of H2O2
(Figure 4.5).

Figure 4.5 The effect of H2O2 concentration on ATV transformation
ROX=25 µM, CPO=4.8 nM, phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH=3.5,
H2O2= 0, 0.07, 0.17, 0.34, 0.52, 0.69, 1.03 and 1.38 mM respectively.
Monitored by UV at λ=223nm

As expected, there is no transformation observed without the addition of H2O2.
The rate of transformation is greatly enhanced as the concentration of H2O2
increased up to 0.69 mM. However, further increase in H2O2 concentration (from
0.69 to 1.38 mM) decreased the reaction rate. The possible explanation could be
that excess H2O2 deactivates the enzyme by forming a highly reactive iron peroxyl
species which leads to heme degradation [62]. Thus, low concentrations of H2O2
is applied for CPO induced transformation of ROX.
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4.3.4 Michaelis-Menten kinetics
CPO-catalyzed degradations generally follow Michaelis-Menten kinetics, an
established model of single substrate kinetics showing the relation between the
substrate concentration and reaction rate. The form of Michaelis-Menten equation
is given as:

V=

𝑉𝑚𝑎𝑥 × [𝑆]
𝐾𝑚 + [𝑆]

Where S is the concentration of the substrate (ROX), V is the initial reaction rate
measured in the linear range of transformation. Vmax is the maximum rate that can
be achieved by the system and Km is the substrate concentration at which the
reaction rate is half of Vmax. Km, known as the Michaelis constant, indicates the
affinity of the substrate to the enzyme, and the value depends on both of them, as
well as conditions such as pH and temperature.

1
𝐾𝑚
1
1
=
×
+
𝑉 𝑉𝑚𝑎𝑥 [𝑆] 𝑉𝑚𝑎𝑥

Figure 4.6 Lineweaver–Burk plot

Lineweaver-Burk plot was used to calculate Michaelis-Menten constant (Km) and
maximum reaction rate (Vmax). Plotting the inverse of substrate concentration and
initial rate, yields a straight line that permits the determination of Km and Vmax.
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To conduct the experiment, different concentrations of ROX were dissolved in the
buffer solution. Initial transformation rates were calculated by monitoring
absorbance at 223 nm from 12-24 seconds.

Figure 4.7 Michaelis-Menten kinetics
CPO=4.8 nM, H2O2= 0.69 mM, phosphate buffer: 100 mM K2HPO4, 20 mM KBr, pH=3.5,
ROX= 0, 5.1, 6.3, 12.7, 25.3, 38.0, 50.7, 76.0, and 101.4 µM respectively.
Monitored by UV at λ=223nm

From the plot, the kinetic parameter were obtained with a Michaelis-Menten
constant (Km) of 23.61 µM and maximum reaction rate (Vmax) of 3.98 µM min-1.
Based on the parameter calculated, turnover number can be determined to give
the maximum number of conversions of substrate molecules per second that a
single catalytic site will execute for a given enzyme concentration.

𝑘𝑐𝑎𝑡 =

𝑉𝑚𝑎𝑥
[𝐸] 𝑇

Vmax is the maximum rate and [E]T is the concentration of catalyst (CPO).
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4.3.5 Product identification

NMR and mass analyses were employed to establish the structure of the products

from CPO-catalyzed transformation of ROX. The proton NMR spectra are shown
in Figure 4.8. The mass spectra are shown in Figure 4.9.

Figure 4.8 Proton NMR of ROX transformation products. The NMR sample was prepared in 100 mM

phosphate buffer containing 20 mM KBr, 0.63 mM ROX, 24 nM CPO and 0.69mM H202 at pH=3.5. Sample
was dissolved in deuterated acetone for NMR detection.
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Figure 4.9 Mass spectra of ROX transformation products. The sample was prepared in 100 mM phosphate buffer containing 20
mM KBr, 0.63 mM ROX, 24 nM CPO and 0.69mM H202 at pH=3.5. Sample was taking from NMR tube and diluted to 1ppm for
mass detection.
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The transformation of ROX was confirmed by NMR and mass analysis of the
reaction products. The NMR spectra suggested the formation of three products
and two of them were shown on the mass spectra. The molecular ion detected on
mass indicated the addition of two bromine atom to the parent compound, since a
1:2:1 ratio of M:M+2:M+4 peaks is the isotopic signature of two bromine. The
single bromination product was not observed in mass spectrum but gave two
doublets at 7.98 and 8.16 ppm in NMR with a coupling constant around 4, which
indicates the addition of one bromine to the meta carbon of the hydroxyl group.
The 264, 266 and 268 m/z ratio, together with the single peak in NMR at 8.11 ppm
are consistent with the formation of a di-brominated product. Two positions exist
as another bromine can be added at the benzene ring. However, the meta
position carbon of the nitro group is less preferred because of the effect of steric
hindrance and electronic directing effect of the nitro group. Therefore, the addition
is proposed to be at the para position of the nitro group. The coupling pattern of
this product indicates the hydroxylation of the nitro group, resulting in a doublet of
doublets and two doublets in NMR, giving 264, 266 and 268 m/z ratio in mass
spectra with two bromine added. The molecular ions are not shown in the mass
spectra for the easily decomposed characteristic of ROX and related metabolites.
However, the fragmentation ions observed is in good agreement with the products
proposed by NMR.
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4.3.6 Mechanism of CPO-catalyzed roxarsone transformation
Based on the products identified from NMR and mass spectroscopic studies, a
mechanism of CPO-catalyzed transformation of ROX is proposed (Figure 4.10).

Figure 4.10 Proposed mechanism of ATV transformation (C=Cl- or Br-)
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4.4 Conclusion
In this work, we found that ROX is effectively transformed by CPO. The
transformation can be achieved over a range of acidic pH (2.5 to 5) with the
fastest transformation observed at pH = 3.5. The conversion required H2O2 with
an optimal concentration range of 0.4-1 mM. The CPO catalyzed transformation
of ROX followed Michaelis-Menten kinetics, with an Km of 23.61 µM and Vmax of
3.98 µM min-1. These parameters can be used as a measure for the preference of
CPO to ROX and also to evaluate the effectiveness of the enzyme.

Both NMR and MS analyses demonstrated the bromination and hydroxylation of
aromatic ring in ROX, showing the regioselectivity of CPO catalysis. During
bromination, CPO converts ROX to either monobrominated (3-bromo-4-hydroxy-5
-nitrophenyl arsonic acid) or dibrominated (2,3-dibromo-4-hydroxy-5-nitrophenyl
arsonic acid) products while the nitro group of ROX is hydroxylated. Based on the
product identified, the mechanism of CPO-catalyzed transformation of ROX is
proposed. The CPO-hypohalous acid complex is critical in the transformation in
the proposed mechanism. The product analysis not only provides a better
understanding of CPO catalyzed reactions, but also helps to evaluate the
potential of this enzymatic method in environmental applications. While the
process does not lead to mineralization, the observed product may be less toxic,
more soluble, and more susceptible to further remediation processes.
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In general, the study provides a foundation for assessing the feasibility of applying
CPO in the transformation of ROX contaminated water and soils for its high
efficiency, cost-effectiveness and environmental friendly nature. This study also
provides evidence about the general bromination mechanisms, which has
promising potential in environmental applications. However, there are limitations
such as the requirement for acidic conditions and the limited commercial
availability of CPO.
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